Cassava is advancing simufilam through a pivotal phase 3 trial, despite lingering controversy from a SEC investigation. As the company prepares to release trial results, Ben Hargreaves finds that ...

SEC adopts EDGAR Next - As outlined in this October 22 Cooley alert, the Securities and Exchange Commission (SEC) adopted final ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

Detailed price information for Cassava Sciences Inc (SAVA-Q) from The Globe and Mail including charting and trades.

Digital protection company Cloudflare has announced that it has selected Liquid C2, a Cassava Technologies business unit, to ...

Cassava Sciences, Inc. (SAVA) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces ...

Bullish option flow detected in Cassava Sciences (SAVA) with 4,488 calls trading, 1.2x expected, and implied vol increasing almost 28 points to 375.05%. Nov-24 35 calls and Nov-24 30 calls are the ...

SAN FRANCISCO (KRON) — Cassava, an award-winning French-California bistro in San Francisco’s North Beach neighborhood, is closing after 12 years in business. In a post on Instagram ...

AUSTIN, Texas - Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotech company, announced today that an independent Data and Safety Monitoring Board (DSMB) has completed a... ByInvesting ...

Investing.com - Cassava Sciences (NASDAQ:SAVA) reported on Monday third quarter earnings that missed analysts' forecasts and revenue that was in line with expectations. Cassava ...